Patents by Inventor Helmut Knoller
Helmut Knoller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150297738Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: June 29, 2015Publication date: October 22, 2015Inventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Publication number: 20140088298Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxy-yalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: March 27, 2014Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Publication number: 20140073778Abstract: The present invention relates to hydroxyalkyl starch conjugates, a method for preparing the same, the hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent and the cytotoxic agent comprising at least one tertiary hydroxyl group, wherein the hydroxyalkyl starch is linked via said tertiary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: March 13, 2014Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken
-
Publication number: 20140073779Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: March 13, 2014Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Publication number: 20130230898Abstract: The invention relates to a method for the preparation of a hydroxyalkyl starch derivative which comprises reacting hydroxyalkyl starch (HAS) via the optionally oxidised reducing end of the HAS with the amino group M of a crosslinking compound which, apart from the amino group, comprises a specifically protected carbonyl group, namely an acetal group or a ketal group.Type: ApplicationFiled: February 19, 2013Publication date: September 5, 2013Applicant: Fresenius Kabi Deutschland GmbHInventors: Frank Hacket, Thomas Hey, Franziska Hauschild, Helmut Knoller, Martin Schimmel, Klaus Sommermeyer
-
Publication number: 20130217871Abstract: The present invention relates to hydroxyalkyl starch conjugates and a method for preparing the same, the hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one primary hydroxyl group, wherein the hydroxyalkyl starch is linked via said primary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold and a molar substitution (MS) in the range of from 0.6 to 1.5.Type: ApplicationFiled: July 11, 2011Publication date: August 22, 2013Inventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Saswata Lahiri, Nitin Gupta, Vivek Kumar, Mukesh Madan Mudgal
-
Publication number: 20130211060Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxy-yalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: August 15, 2013Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacker, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Publication number: 20130184455Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: July 18, 2013Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Publication number: 20130184454Abstract: The present invention relates to hydroxyalkyl starch conjugates, a method for preparing the same, the hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent and the cytotoxic agent comprising at least one tertiary hydroxyl group, wherein the hydroxyalkyl starch is linked via said tertiary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: July 18, 2013Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken
-
Publication number: 20130178437Abstract: The present invention relates to hydroxyalkyl starch (HAS) conjugates and to a method for preparing the hydroxyalkyl starch (HAS) conjugates, the hydroxyalkyl starch (HAS) conjugates comprising a hydroxyalkyl starch derivative and a cytotoxic agent, said conjugate having a structure according the following formula HAS?(-M)n wherein M is a residue of a cytotoxic agent, the cytotoxic agent comprising a carbonyl group, HAS? is a residue of the hydroxyalkyl starch derivative comprising at least one functional group X, n is greater than or equal to 1, and wherein the cytotoxic agent is linked via the carbonyl function present in the cytotoxic agent to the functional group X comprised in the hydroxyalkyl starch derivative, wherein the linkage via the carbonyl function is a cleavable linkage, which is capable of being cleaved in vivo so as to release the cytotoxic agent.Type: ApplicationFiled: July 11, 2011Publication date: July 11, 2013Applicant: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander
-
Patent number: 8404834Abstract: The invention relates to a method for the preparation of a hydroxyalkyl starch derivative which comprises reacting hydroxyalkyl starch (HAS) via the optionally oxidized reducing end of the HAS with the amino group M of a crosslinking compound which, apart from the amino group, comprises a specifically protected carbonyl group, namely an acetal group or a ketal group.Type: GrantFiled: December 15, 2008Date of Patent: March 26, 2013Assignee: Fresenius Kabi Deutschland GmbHInventors: Frank Hacket, Thomas Hey, Franziska Hauschild, Helmut Knoller, Martin Schimmel, Klaus Sommermeyer
-
Publication number: 20100305033Abstract: The invention relates to a method for the preparation of a hydroxyalkyl starch derivative which comprises reacting hydroxyalkyl starch (HAS) via the optionally oxidised reducing end of the HAS with the amino group M of a crosslinking compound which, apart from the amino group, comprises a specifically protected carbonyl group, namely an acetal group or a ketal group.Type: ApplicationFiled: December 15, 2008Publication date: December 2, 2010Applicant: Fresenius Kabi Deutschland GmbHInventors: Frank Hacket, Thomas Hey, Franziska Hauschild, Helmut Knoller, Martin Schimmel, Klaus Sommermeyer
-
Publication number: 20100297078Abstract: A method of producing a hydroxyalkyl starch (HAS) derivative, comprising a) reacting optionally oxidized hydroxyalkyl starch with a compound (D) comprising at least two functional groups —O—NH2 or a salt thereof, and b) reacting the hydroxyalkyl starch derivative obtained in step a) with a compound (L) comprising at least two functional groups W1 and W2 independently selected from the group consisting of an aldehyde group, a suitably protected aldehyde group, a keto group, and a suitably protected keto group.Type: ApplicationFiled: December 15, 2008Publication date: November 25, 2010Applicant: Fresenius Kabi Deutschland GmbHInventors: Frank Hacket, Wolfram Eichner, Helmut Knoller, Andreas Mitsch, Martin Schimmel, Norbert Zander, Franziska Hauschild
-
Publication number: 20080274948Abstract: The present invention relates to conjugates of hydroxyalkyl starch and a granulocyte colony stimulating factor protein (G-CSF) wherein these conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. The present invention also relates to the methods of producing these conjugates and the use of these conjugates.Type: ApplicationFiled: August 6, 2004Publication date: November 6, 2008Applicant: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Wolfram Eichner, Helmut Knoller, Katherina Lutterbeck, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Sommermeyer, Eckard Grabenhorst
-
Publication number: 20080207562Abstract: The present invention relates to a method for preparing conjugates of an active substance and hydroxyalkyl starch and to conjugates of an active substance and hydroxyalkyl starch, preferably hydroxyethyl starch, wherein the conjugates are prepared by covalently linking the hydroxyalkyl starch and the active substance by a chemical residue having a structure according to formula (I) or formula (I?) or formula (I?) wherein R1, R2, R2?, R3, R3? and R4 are independently selected from the group consisting of hydrogen, an optionally suitably substituted, linear, cyclic and/or branched alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl group, preferably hydrogen.Type: ApplicationFiled: September 12, 2006Publication date: August 28, 2008Applicant: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Norbert Zander, Helmut Knoller
-
Publication number: 20070087961Abstract: Conjugates of hydroxyethyl starch and erythropoietin are provided. The conjugates comprise a linking compound that is covalently linked to erythropoietin and covalently linked to hydroxyethyl starch. Methods of producing the conjugates, and their use, also are provided.Type: ApplicationFiled: September 8, 2006Publication date: April 19, 2007Inventors: Wolfram Eichner, Katharina Lutterbeck, Norbert Zander, Ronald Frank, Harald Conradt, Helmut Knoller
-
Publication number: 20040023913Abstract: The invention relates to a pathogen-inactivating agent, as well as its use, whereby the agent contains an element that binds to nucleic acids of the pathogens, and a conjungate that destroys nucleic acid. The conjungate is created from a metal chelate complex, in which the metal can change between at least two oxidation levels. In particular, the agent can be used in physiological liquids, such as blood, or blood fractions for the inactivation of viruses.Type: ApplicationFiled: April 18, 2003Publication date: February 5, 2004Inventors: Hans-Juergen Neumann, Helmut Knoller